期刊文献+

微创经皮肾镜取石术治疗多囊肾合并肾结石 被引量:5

Minimally Invasive Percutaneous Nephrolithotomy for Calculi in Patients with Polycystic Kidney
下载PDF
导出
摘要 目的 评价微创经皮肾镜取石术(minimally invasive percutaneous nephrolithotomy,MPCNL)治疗多囊肾合并肾结石的疗效和安全性。方法 分析我院2007~2013年16例多囊肾合并肾结石患者接受MPCNL的临床资料。结果 16例均成功建立皮肾通道,平均手术时间40min,平均出血30mL,结石清除率93.75%。手术前后血红蛋白、血肌酐比较,差异无统计学意义(P〉0.05),1月后血肌酐值下降至(142.69±76.28)μmol/L(P〉0.05),无输血或血管栓塞病例。随访3~12个月,血红蛋白和血肌酐值稳定,结石无复发,肾囊肿无增大。结论 MPCNL是安全、有效治疗多囊肾合并肾结石的方法之一。 Objective To evaluate the efficacy and safety of minimally invasive percutaneous nephrolithotomy(MPCML)for calculi in patients with polycystic kidney.Methods The clinical datum of 16 patients with renal stones complicated with polycystic kidney who accepted the MPCML were assessed from 2007 to 2013in our hospital.Results The percutaneous nephrostomy channel was successfully established under B-type ultrasound guidance in all patients at the first time.Operation time ranged from 30 to 90minutes,that is,the average time was40 minutes,and blood loss ranged from 5to 60 mL(mean 30 mL).The clearance of the stone at one session was93.75%(15/16).The hemoglobin decreased by 10.2g/L.There were no significant differences in the hemoglobin before and after operation[(136.75±6.34)g/L,(121.24±6.67)g/L,P〉0.05].There were no significant changes in the serum creatinine levels before and after MPCNL[(168.34±102.57)μmol/L,(165.76±92.24)μmol/L,P〉0.05].The mean serum creatinine level was slightly decreased(142.69±76.28)μmol/L at 1-month follow-up without blood transfusion or Selective renal artery embolization.There were no difference between hemoglobin and renal function.What's more,there still were no stone recurrence and no enlargement in the cyst in the 3-12 months following up.Conclusion MPCNL is safe and reliable way for the treatment of stones in the patients with polycystic kidney.
出处 《成都医学院学报》 CAS 2014年第6期716-718,共3页 Journal of Chengdu Medical College
关键词 肾结石 多囊肾 微创经皮肾镜取石术 Kidney calculi Polycystic Kidney Minimally invasive percutaneous nephrolithotomy
  • 相关文献

参考文献9

  • 1Mao Z, Xie G, Ong AC. Metabolic abnormalities in autosomal dominant polycystic kidney disease [J]. Nepbrol Dial Transplant, 2014 ( 2 ) : 235.
  • 2Umbreit EC, Adam M, David E, et al. Pereutaneous nephrolithotomy for largeor multiple upper tract calculi and autosomal dominantpolyeystic kidney disease [J]. J Urol, 2010,183( 1 ) : 183-187.
  • 3Singh V, Sinha R J, Gupta DK. Pereutaneous Nephrolithotomy in Autosomal Dominant Polycystie Kidney Disease: Is it Different from Percutaneous Nephrolithotomy in Normal Kidney? :]:.Curr Urol,201:,7(1):7 13.
  • 4Zhang J, Zhang J,Xing N. Polycystie kidney disease with renal calculi treated by percutaneous nephrolithotomy:a report of 11 cases [J]. Urol 1nt,2014,92(4):427-432.
  • 5Ordon M, Urbach D, Mamdani M, et al. The surgical management of kidney stone disease: a population based time series analysis [J]. J Urol,2014,192(5) : 1450-1456.
  • 6Agarwal M,Agrawal MS,Jaiswal A,et al. Safety and efficacy of ultrasonography as an adjunct to fluoroscopy for renal access in percutaneous nephrolithotomy (PCNL) [J]. BJU Int, 2011, 108(87:1346-1349.
  • 7Gain baro G, Fabris A, Puliatta D, et al. I.ithiasis in cystic kidney disease and malformations of the urinary tract [J]. Urol Res, 2006,34 (2) : 102-107.
  • 8Srivastava A, Bansal R, Srivastava A, et al. Percutaneous nepbrolithotomy in polycystic kidney disease., is it safe and effective? [J]. Int Urol Nephrol,2012,44(3):725-730.
  • 9I.ei M,Zhu W,Wan SP,et al. Safety and Efficacy of Minimally Invasive Percutaneous Nephrolithotomy in Patients with Autosomal Dominant Polycystic Kidney Disease [J]. J Endourol,2014,28(1) :17-22.

同被引文献41

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部